PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12188416::ACT019240

tyroserleutide

Evidence text

Paper-level observation

mice treated with YSL (8 mg/kg) combined with a higher dose of 5F–C12 (1.6 mg/kg) exhibited an even more pronounced tumor growth inhibition of 81.1% (Figure 6b,d).
textConfidence: medium

Assay observation

Activity
Anticancer
Subtype
Antibacterial
Measure
percent_inhibition
Comparator
=
Raw observation
81.1%
Normalized measurement
=81.1%
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
MCF-7
Assay method
Not reported by source
Sequence
YSL
Standardization
ready simple

Source publication

Artificial Tyroserleutide Transporters for Synergistic Cancer Therapy.

JACS Au · 2025

DOI 10.1021/jacsau.5c00204 PMC12188416
Parent mention Integrated peptide

Related peptide identities

PEPDIA-PLP-004213PEPDIA-INT-025613

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.